Worldwide Clinical Trials | Oncology

Beyond a Single Disease: Traversing Complexity in Breast Cancer Clinical Development

Breast cancer is the most commonly diagnosed cancer among women worldwide and the second most common cancer overall, with an estimated 2.3 million new cases and 670,000 deaths globally in 2022 (Kim et al., 2025; Bray et al., 2024).[1,2] By 2050, new cases are projected to increase ~38% and deaths closer to a 68% increase, largely in countries with lower resources (Kim et al., 2025).[1] Yet breast cancer clinical development is advancing quickly. Precision medicine, biomarker-defined patient populations, novel therapeutic modalities, and sophisticated trial designs have collectively transformed patient possibilities, while simultaneously raising the operational bar for sponsors. For biotech and emerging biopharma companies developing novel breast cancer therapies, the path from an early-stage program to regulatory approval demands an expert-level understanding of the science, clinical landscape, and operational factors that determine success.

How is The Treatment Paradigm Changing?

Breast cancer is highly heterogeneous; differences in tumor biology, biomarkers, disease progression, and treatment response require increasingly targeted development strategies across the clinical lifecycle. The disease is fundamentally defined by receptor status (i.e., hormone receptor–positive (HR+), HER2+, and triple-negative (TNBC)), each dictating distinct treatment pathways and presenting different development challenges.

Molecular profiling has revealed even deeper heterogeneity. Gene-expression studies have identified intrinsic subtypes, such as luminal A, luminal B, HER2 enriched, and basal-like, all with distinct genomic landscapes, prognoses, and therapeutic vulnerabilities (Swarbrick et al., 2024).[3] Even within HR+/HER2− disease, recent multi-omics work has uncovered subtypes (e.g., canonical luminal, immunogenic, proliferative, and receptor tyrosine kinase–driven) that respond differently to therapy and may warrant subtype-specific strategies (Jin et al., 2023).[4] For sponsors, this diversity creates both opportunity and complexity, because precision development can improve fit, but also demands tighter targeting and planning.

The treatment landscape has been transformed across subtypes. The 1998 approval of trastuzumab for HER2+ breast cancer marked a breakthrough credited with saving an estimated three million lives, and the field has continued to advance. Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan established a new standard of care for HER2 low metastatic breast cancer, significantly improving both progression-free and overall survival versus chemotherapy in the DESTINY-Breast04 trial (Modi et al., 2022).[5] ADCs are now expanding beyond HER2 into targets such as TROP2 and moving into earlier lines of treatment (Kamal et al., 2026).[6]

In HR+/HER2− disease, CDK4/6 inhibitors have entered curative-intent treatment, with adjuvant abemaciclib and ribociclib both demonstrating durable disease-free survival benefits, and, more recently, overall survival improvement, in high-risk early breast cancer (Rastogi et al., 2024; Hortobagyi et al., 2025).[7,8] In early-stage TNBC, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has become the standard of care, with the KEYNOTE-522 trial confirming a significant overall survival benefit (Schmid et al., 2024).[9] These advances underscore how quickly the standard of care evolves, so sponsors must anticipate this moving target when designing trials.

How Does This Impact Biomarker-Driven Development & Associated Complexity?

The shift toward precision oncology has fundamentally altered how breast cancer trials are designed and executed. Patient selection increasingly depends on comprehensive molecular profiling, access to validated assays, and an understanding of co-mutations and resistance mechanisms. Biomarker-driven development means that assay strategy, companion diagnostic planning, and sample collection protocols must be built into program design from the earliest stages.
TNBC illustrates both the opportunity and the difficulty. As a highly heterogeneous disease lacking the actionable receptors that define other subtypes, TNBC has limited biomarker-driven treatment options beyond germline BRCA1/2 status and PD-L1 expression, and outcomes in metastatic disease remain poor despite years of research (Punie et al., 2025; Alobaidi & Rai, 2026).[10,11] Finding reliable predictive biomarkers through multi-omics integration, tumor-infiltrating lymphocytes, and molecular subtyping is an active and critical area of investigation (Alobaidi & Rai, 2026).[11]
For sponsors, this means that TNBC programs must plan for complex inclusion/exclusion criteria, evolving biomarker strategies, and the operational challenge of identifying the right patients in a disease that resists simple classification.

Adaptive platform trials, basket and umbrella designs, and master protocols are increasingly used to accelerate development and maximize signal detection across biomarker-defined subpopulations. These designs offer significant scientific advantages but require careful operational planning, robust data management infrastructure, and experienced clinical teams who understand both the scientific intent and the regulatory implications of adaptive decision rules. For emerging biotech sponsors navigating these choices for the first time, the learning curve can be steep, and the cost of a poorly executed protocol revision is high.

What Are Persistent Enrollment & Site Selection Operational Challenges?

Even the most elegantly designed protocol cannot overcome a fundamental enrollment challenge. Breast cancer has the highest number of clinical trials and the highest funding of any cancer type, creating one of the most competitive research environments in oncology. Sponsors competing for the same molecularly characterized patients across multiple simultaneous trials should prioritize site selection, investigator relationships, and pre-screening efficiency as much as scientific positioning.

Data-driven site selection that includes historical enrollment performance, site infrastructure, molecular testing capabilities, and competitive trial density is essential for setting realistic timelines and managing sponsor expectations. Because many breast cancer patients have undergone multiple lines of therapy, finding treatment-naïve patients in North America and Western Europe can be particularly challenging when trials require it. Early engagement with experienced investigators, pre-screening programs that identify eligible patients before a trial opens, and real-time enrollment monitoring are operational tools that can meaningfully accelerate recruitment.

Diversity in trial participation remains a persistent and consequential challenge. Mortality from breast cancer is approximately 40% higher among Black women than White women. Yet, enrollment of Black patients in breast cancer trials has historically been as much as 11-fold lower than that of White patients (Taye et al., 2024).[12] This underrepresentation undermines the generalizability of trial results and perpetuates outcome gaps. Sponsors should build diversity into site selection and recruitment planning from the outset to generate data that reflect the populations their therapies aim to serve and meet growing regulatory expectations around representative enrollment.

What Are Some Early Phase vs. Later-Phase Development Considerations?

The strategic priorities of breast cancer development shift across phases. Phase I programs, including first-in-human studies and basket trials, prioritize rapid signal detection, safety characterization, and biomarker-driven dose finding. Sponsors should align site alliances, site activation, and first-patient-in goals with that need for speed. Later-phase and registrational studies demand broader global footprints, robust endpoint adjudication, and the operational discipline to run large, multi-country trials that can support regulatory submissions across jurisdictions.

For emerging biotech and biopharma companies bringing a breast cancer asset into clinical development, the current landscape presents both a challenge

and an opportunity. The challenge includes potential constraints related to internal infrastructure, compressed timelines, and the need to make high-stakes decisions about biomarker strategy, trial design, site selection, and geographic scope. The opportunity lies in the fact that a well-designed, efficiently executed breast cancer trial can generate data that attract partnership interest, support regulatory interaction, and competitively position a program in a crowded field.

Worldwide's Commitment to Breast Cancer Development

Breast cancer clinical development is among the most scientifically rich and operationally demanding areas in oncology today. The convergence of precision medicine, ADCs, cell therapies, immunotherapy, and combination approaches is driving unprecedented development activity, making efficient execution essential in an increasingly competitive, biomarker-driven, and global clinical development landscape. Success requires deep therapeutic expertise, operational excellence, strong site relationships, and the flexibility to support innovative development strategies across all stages.

Worldwide Clinical Trials brings this combination to every breast cancer program it supports. As a specialist oncology CRO with the global reach and operational scale of a large CRO and the deep expertise and focus of a boutique oncology provider, Worldwide has supported more than 40 breast cancer trials over the past five years, enrolling over 4,300 patients across 25 countries and 350+ unique sites. With oncology expertise embedded across all functions and an average of 11+ years of oncology experience per team member, Worldwide delivers data-driven site and country selection, industry-leading study start-up performance ranking in the top 15th percentile versus industry benchmarks, and a flexible service model tailored to the unique needs of development-stage biotechs and emerging biopharma companies alike. From first-in-human studies to registrational trials, Worldwide is built to support sponsors at every stage of their breast cancer development journey.

References

1. Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM. Global Patterns and Trends in Breast Cancer Incidence and Mortality Across 185 Countries. Nat Med. 2025 Apr;31(4):1154-1162. PMID: 39994475. doi: 10.1038/s41591-025-03502-3.

2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. PMID: 38572751. doi: 10.3322/caac.21834.

3. Swarbrick A, Fernandez-Martinez A, Perou CM. Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity. Cold Spring Harb Perspect Med. 2024 Jan 2;14(1):a041320. PMID: 37137498. PMCID: PMC10759991. doi: 10.1101/cshperspect.a041320.

4. Jin X, Zhou YF, Ma D, Zhao S, Lin CJ, Xia Y, Fu T, Liu CL, Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX, Huang W, Robertson JFR, Jiang YZ, Shao ZM. Molecular Classification of Hormone Receptor-Positive HER2-Negative Breast Cancer. Nat Genet. Oct;55(10):1696-1708. PMID: 37770634. doi: 10.1038/s41588-023-01507-7.

5. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF ... Cameron DA. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. PMID: 35665782. PMCID: PMC10561652. doi: 10.1056/NEJMoa2203690.

6. Kamal A, Shahin H, Beddah A, Alshahrani MM, Salami A, Sohaib A. The Emerging Role of Antibody-Drug Conjugates in Breast Cancer: A Systematic Review of Clinical Evidence. Onc Clin Pract. 2026;22:e00526120.

7. Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer: 5-Year monarchE Outcomes. J Clin Oncol. 2024 Jan 9;42(9):987–993. PMCID: PMC10950161. PMID: 38194616. doi: 10.1200/JCO.23.01994.

8. Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. A Phase III Trial of Adjuvant Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in Patients With HR-Positive/HER2-Negative Early Breast Cancer: Final Invasive Disease-Free Survival Results From the NATALEE Trial. Ann Oncol. 2025 Feb;36(2):149-157. PMID: 39442617. doi: 10.1016/j.annonc.2024.10.015.

9. Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024 Nov 28;391(21):1981-1991. PMID: 39282906. doi: 10.1056/NEJMoa2409932.

10. Punie K, Kurian AW, Ntalla J, Sjekloca N, Estrin A, Dabrowski EC, Lai C, Hurvitz S. Unmet Need for Previously Untreated Metastatic Triple-Negative Breast Cancer: A Real-World Study of Patients Diagnosed From 2011 to 2022 in the United States. Oncologist. 2025 Mar 31;30(3):oyaf034. PMCID: PMC11957248. PMID: 40163689. doi: 10.1093/oncolo/oyaf034.

11. Alobaidi A, Rai V. Triple-Negative Breast Cancer: Current Understanding and Future Perspectives. Explor Target Antitumor Ther. May 14:7:1002372. PMID: 42147479. PMCID: PMC13176762. doi: 10.37349/etat.2026.1002372.

12. Taye A, Elkhanany A, Stringer-Reasor E. Increasing Inclusion and Equity for Black Women in Breast Cancer Clinical Trials. Clin Adv Hematol Oncol. 2024 May;22(4):175-182. PMID: 38739720.

08202026